inflammatory disease

Immune and inflammatory diseases such as psoriasis, arthritis and inflammatory bowel disease, and the drugs for them.

Theme · 14 companies · 3 report it as a revenue line

Show
8-K events
Match any selected event
8-K event types
More events

Only filters 8-Ks. Other selected forms stay visible.

Role
  • ABBV AbbVie

    Sells it“Rinvoq (upadacitinib) is an oral, once-daily selective and reversible JAK inhibitor that is approved to treat the following inflammatory diseases in North America, the European Union and Japan:”

    Latest 10-QQ3 FY2026Positive ·

    Skyrizi and Rinvoq more than offset Humira erosion; lower acquired R&D and impairment charges amplify the earnings rebound.

    • Revenue$17.4BYoY +10.3%
    • Net income$4.2Bvs $186.0M year ago
  • AMGN Amgen

    Sells it 12%, $4.5B a year“Otezla is an oral therapy approved for the treatment of adults with plaque psoriasis across all severities (in the United States, Japan and Australia) and moderate-to-severe plaque psoriasis (in other global markets, including Europe); for adults with active psoriatic arthritis; for adults with oral ulcers associated with Behçet’s disease; and for pediatric patients six years of age and older and weighing at least 20 kilograms with moderate-to-severe plaque psoriasis who are candidates for phototherapy or systemic therapy.”

    Latest 10-QQ3 FY2026 ·

    Repatha, UPLIZNA and IMDELLTRA demand more than offsets biosimilar erosion in Prolia and XGEVA.

    • Revenue$10.4BYoY +8.5%
    • Net income$3.9BYoY +20.1%
  • ATTO Attovia Therapeutics, Inc.

    In development“We are developing a pipeline of novel biotherapeutics for the treatment of immune-mediated diseases (Figure 1).”

    Latest 424B4final IPO prospectusPositivePre-revenue ·

    Develops immune-disease biologics using ATTOBODY; $289M all-primary raise backs clinical validation of itch treatment ATTO-1310.

  • BBTX Bambusa Therapeutics, Inc.

    In development“Our pipeline is focused on four bispecific antibody programs for the treatment of a broad range of I&I indications, as shown in Figure 5 below.”

    Latest 424B4final IPO prospectusPositiveBankruptcy / going concernAccounting issueImpairment / charge ·

    Develops dual-target antibodies for eczema and respiratory diseases; $169M raise funds trials of BBT001 and BBT002.

  • BMY Bristol-Myers Squibb

    Sells it 8%, $4.0B a year“Orencia (abatacept) is a biologic and a fusion protein indicated for (i) the treatment of adult patients with moderately to severely active RA, (ii) the treatment of patients 2 years of age and older with moderately to severely active polyarticular JIA, (iii) the treatment of patients 2 years of age and older with active PsA and (iv) the prophylaxis of aGVHD, in combination with a calcineurin inhibitor and methotrexate in certain adult and pediatric patients.”

    Latest 10-QQ3 FY2026MixedImpairment / charge ·

    Eliquis drove growth as generics eroded Revlimid and Pomalyst; pipeline licensing charges weighed on earnings.

    • Revenue$13.1BYoY +6.9%
    • Net income$2.2BYoY −1.8%
  • ETRA Electra Therapeutics, Inc.

    In development“We are also advancing ELA822, a novel SIRPg-specific monoclonal antibody designed to selectively deplete activated T cells, with potential applications across chronic T cell-mediated immune and inflammatory diseases.”

    Latest 424B4final IPO prospectusMixedBankruptcy / going concernPre-revenue ·

    Develops antibodies to remove disease-driving immune cells; $350M all-primary raise funds ipsoprubart’s registrational trials

  • IAM Iambic Therapeutics, Inc.

    Supplies it“Our relationships with leading partners like AbbVie, Takeda, Lundbeck, NVIDIA, Lambda, Revolution Medicines, Jazz Pharmaceuticals, and Bayer demonstrate meaningful external interest in our platform, and are expanding the impact of our platform to additional target classes (for example, G protein-coupled receptors), additional therapeutic indications (for example, neurology, gastrointestinal, inflammation and immunology), and additional small-molecule mechanisms of action (for example, molecular glues, and glue degraders).”

    Latest 424B4final IPO prospectusPositivePre-revenueCustomer concentration ·

    AI-driven drug developer raises $150M to advance lead HER2 cancer candidate IAM1363 and its pipeline

  • JNJ Johnson & Johnson

    Sells it“Immunology (e.g., rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease and psoriasis)”

    Latest 10-QQ3 FY2026MixedRestructuringImpairment / chargeLegal / investigation ·

    TREMFYA and oncology growth offset STELARA’s biosimilar erosion, but a proposed talc-settlement charge nearly wiped out earnings.

    • Revenue$25.4BYoY +5.9%
    • Net income$210.0MYoY −95.9%
  • LLY Eli Lilly and Company

    Sells it 8%, $5.2B a year“For the treatment of adults and pediatric patients aged 6 years or older with moderate to severe plaque psoriasis; adults with active psoriatic arthritis; adults with ankylosing spondylitis; and adults with active non-radiographic axial spondyloarthritis.”

    Latest 10-QQ3 FY2026PositiveImpairment / charge ·

    Mounjaro and Zepbound volume growth outweighed lower prices, while acquired research charges constrained profit growth.

    • Revenue$24.4BYoY +38.6%
    • Net income$6.5BYoY +15.5%
  • LYCA Lycia Therapeutics, Inc.

    In development“Our initial focus is on autoimmune, inflammatory and allergic diseases that are characterized by large patient populations, significant unmet need and well-validated disease biology that support clear applications for our LYTAC technology.”

    Latest 424B4final IPO prospectusMixedPre-revenue ·

    Develops protein degraders for food allergy and Graves’ disease; raises $318M gross to advance clinical trials.

  • PFE Pfizer

    Sells it“Inflammation & immunology product portfolio – select products include: Xeljanz, Enbrel (outside the U.S. and Canada), Cibinqo, Litfulo, Eucrisa and Velsipity.”

    Latest 8-KCEO/CFO change ·

    Interim CFO Cecile Guegan appointed permanent CFO and EVP, effective Nov. 1.

  • RZRA Rezera Inc.

    In development“By directly inhibiting NLRP3 upstream, we aim to broadly reduce the activity of the entire sterile inflammation pathway, thereby reducing RIR and modifying the course of cardiovascular and neurologic diseases.”

    Latest S-1/Aamended IPO prospectusBankruptcy / going concernAccounting issueCEO/CFO change ·

    Develops oral anti-inflammatory drugs; IPO funds a pivotal ruvonoflast trial in peripheral artery disease, its first test in these patients.

  • SDGR Schrödinger, Inc.

    Supplies it“We have entered into drug discovery collaborations with biopharmaceutical companies under which our collaborators are pursuing research in a number of therapeutic areas, including programs in oncology, antifungal diseases, fibrosis, inflammatory bowel disease, metabolic disease, autoimmune disease, immuno-oncology, cardiopulmonary disease, CNS diseases, and tuberculosis.”

    Latest 10-QQ3 FY2026 ·

    Structure Therapeutics milestone drove revenue growth; hosted migration obscured stronger software contracting.

    • Revenue$64.5MYoY +18.7%
    • Net income−$37.7MYoY −15.0%
  • WWB WINDWARD BIO GROUP AG

    In development“Our mission is to transform the treatment paradigm for patients living with chronic inflammatory diseases through the development of differentiated biologic therapies targeting validated disease pathways.”

    Latest 424B4final IPO prospectusPositivePre-revenue ·

    Develops long-acting antibodies for asthma and other inflammatory diseases; $175M raise funds trials led by WIN378’s potential twice-yearly dosing

Feedback